For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...

The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms ...

SpringWorks Therapeutics ( NASDAQ: SWTX) soared ~40% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions ...

Merck's German-listed shares closed down 3.7%. Stamford, Connecticut-based SpringWorks, which listed its shares in New York in 2019, is a commercial-stage biotech firm that develops drugs to treat ...

EST SpringWorks shares up 39% to $55.90 after Merck KGaA (MKGAY) confirms talksMaximize Your Portfolio with Data Driven Insights:Leverage ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...